{"id":"W4406486248","doi":"10.1136/bmjophth-2024-001967","title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","year":2025,"lang":"en","type":"review","venue":"BMJ Open Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; University of Ottawa; University of Toronto","funders":"Novo Nordisk; Apellis Pharmaceuticals; Regeneron Pharmaceuticals; Alimera Sciences; Bausch Health; Astellas Pharma; F. Hoffmann-La Roche; Biogen","keywords":"Macular degeneration; Medicine; Ophthalmology; Ranibizumab; Visual acuity; Retina; Retinal; Vascular endothelial growth factor; Vitrectomy; VEGF receptors; Bevacizumab; Surgery; Internal medicine; Neuroscience; Chemotherapy; Psychology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000423335,0.0005772832,0.002195068,0.0001759666,0.0002759412,0.0001739869,0.001169483,0.0002013497,0.00136933],"category_scores_gemma":[0.0005979454,0.0003321455,0.0006819057,0.0005286799,0.00004130028,0.0001075655,0.0006330232,0.0005043819,0.0003560087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002309385,"about_ca_system_score_gemma":0.001991224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001202798,"about_ca_topic_score_gemma":0.000002459065,"domain_scores_codex":[0.9966897,0.0008929572,0.0008483962,0.0008876035,0.0002708339,0.0004105085],"domain_scores_gemma":[0.9959607,0.001920699,0.0004185638,0.001408447,0.0001240631,0.0001674965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000189653,0.0005282164,0.0006489216,0.001325873,0.0004030519,0.0003885026,0.00005240257,3.127203e-7,3.359265e-7,0.00002700028,0.006894919,0.9895408],"study_design_scores_gemma":[0.0007945789,0.0003849059,0.002675344,0.06908433,0.001042186,0.0002786591,0.00002900446,0.000004084292,6.72224e-7,0.00007480838,0.9253018,0.0003296187],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001878521,0.9790006,0.00004880568,0.006471341,0.001091567,0.0108503,0.0002195006,0.00002929957,0.002100749],"genre_scores_gemma":[0.0005303429,0.9906826,0.000544967,0.001590971,0.0002379515,0.004751299,0.0009857561,0.00005798499,0.0006181427],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9892112,"threshold_uncertainty_score":0.999913,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.373294687787905,"score_gpt":0.5592249945097021,"score_spread":0.1859303067217971,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}